Table of contents
February 2008 Vol 7 No 2
In this issue
p103 | doi:10.1038/nrd2528
Editorial: The drought continues
p105 | doi:10.1038/nrd2529
News and Analysis
2007 FDA drug approvals: a year of flux | PDF (401 KB)
p107 | doi:10.1038/nrd2514
News in Brief
UK's NICE under scrutiny | Public–private partnership to improve drug development gets 2 billion euro go-ahead | Access to experimental drugs appeal rejected | Acute preclinical toxicity tests deemed unnecessary | Genzyme backs antisense technology in US$1.9 billion agreement | Big pharma make preclinical deals to tackle schizophrenia | PDF (1,058 KB)
p110 | doi:10.1038/nrd2515
Patent watch
An Audience With
Stephen Friend | PDF (136 KB)
p114 | doi:10.1038/nrd2509
From the analyst's couch
Therapeutic area crossroads: anti-angiogenesis | PDF (244 KB)
p115 | doi:10.1038/nrd2507
Fresh from the Pipeline
Raltegravir | PDF (251 KB)
p117 | doi:10.1038/nrd2512
Research Highlights
Anticancer drugs: Reversing resistance | PDF (294 KB)
p119 | doi:10.1038/nrd2525
Antivirals: Helping hand for HIV | PDF (221 KB)
p120 | doi:10.1038/nrd2523
Anticancer drugs: Redesigning kinase inhibitors | PDF (222 KB)
p120 | doi:10.1038/nrd2524
High-content screening: Integrating information | PDF (162 KB)
p121 | doi:10.1038/nrd2522
Chemogenomics: A change of tactic | PDF (282 KB)
p122 | doi:10.1038/nrd2521
In brief
Kidney diseases | Kinase inhibitors | Lung Disease | PDF (286 KB)
p122 | doi:10.1038/nrd2526
Perspectives
Opinion
Gut microbiota: a potential new territory for drug targeting
腸内細菌叢：薬物標的の新しい領域
Wei Jia, Houkai Li, Liping Zhao & Jeremy K. Nicholson
p123 | doi:10.1038/nrd2505
The emerging influence of intestinal microorganisms on human health has led to the prospect of modulating gut microbiota composition as a novel therapeutic strategy. In this article, Jia and colleagues discuss the rationale behind this approach, identify conditions to which this may be applied, and suggest technologies and strategies for the development of gut microbiota-targeted therapies.
Reviews
Derive and conquer: sourcing and differentiating stem cells for therapeutic applications
分化攻略：治療に応用するための幹細胞の獲得と分化
Irina Klimanskaya, Nadia Rosenthal & Robert Lanza
p131 | doi:10.1038/nrd2403
The success of stem-cell-based therapies depends on finding reliable sources of multipotent and pluripotent cells, and the ability to generate desired derivatives. Here, the authors discuss problems associated with the sourcing of human embyonic stem cells and discuss the current status of stem-cell differentiation technology.
Is raising HDL a futile strategy for atheroprotection?
HDL増大は動脈硬化予防にとって無益な戦略なのか
Tisha Joy & Robert A. Hegele
p143 | doi:10.1038/nrd2489
Raising high-density lipoprotein cholesterol (HDL-C) levels has attracted considerable interest as an approach for the treatment of cardiovascular disease. However, the failure of the HDL-raising investigational drug torcetrapib in clinical trials has led to significant doubts about the potential of this strategy. This article considers possible reasons for the failure of torcetrapib, and discusses alternative agents and strategies that might effectively, and safely, raise HDL-C.
The nitrate–nitrite–nitric oxide pathway in physiology and therapeutics
生理機能および治療における硝酸-亜硝酸-一酸化窒素経路
Jon O. Lundberg, Eddie Weitzberg & Mark T. Gladwin
p156 | doi:10.1038/nrd2466
The supposedly inert end products of endogenous nitric oxide (NO) metabolism — nitrate and nitrite — have recently been shown to be an important alternative source of NO, complementing the classical NO-synthase pathway. Lundberg and colleagues discuss the emerging role of the nitrate–nitrite–NO pathway, highlighting the therapeutic potential of nitrate and nitrite in various disorders, including myocardial infarction, stroke, systemic and pulmonary hypertension, and gastric ulceration.
- 日本語要約 - 55Sf55CG5qmf6IO944GK44KI44Gz5rK755mC44Gr44GK44GR44KL56Gd6YW4LeS6nOehnemFuC3kuIDphbjljJbnqpLntKDntYzot68=
- Full Text
- PDF (2,242 KB)
See also: Correspondence by Panesar | Correspondence by Lundberg et al.
Carbonic anhydrases: novel therapeutic applications for inhibitors and activators
炭酸脱水酵素：阻害剤および活性剤としての新しい治療法
Claudiu T. Supuran
p168 | doi:10.1038/nrd2467
Carbonic anhydrases (CAs) are a large family of ubiquitous metalloenzymes that are involved in many physiological and pathological processes. Traditionally, CA inhibition has been clinically applied in the development of diuretic and antiglaucoma agents. Supuran discusses the emerging potential for inhibitors or activators of CAs to treat a wide range of other disorders, including obesity, cancer, osteoporosis, bacterial and fungal infections, as well as Alzheimer's disease.
Careers and Recruitment
From industry to academia
p183 | doi:10.1038/nrd2513
Corrigendum: Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges
Russell A. Wilke, Debbie W. Lin, Dan M. Roden, Paul B. Watkins, David Flockhart, Issam Zineh, Kathleen M. Giacomini & Ronald M. Krauss
p185 | doi:10.1038/nrd2508
Correspondence
Correspondence: M3 muscarinic receptors as targets for drug development in neurodegenerative disorders
Mike Dragunow
| doi:10.1038/nrd2506-c1
